Complete dosing information for CEMIPLIMAB-RWLC
Medical guidance required: Dosing information here is for educational purposes. Your healthcare provider will determine the appropriate dose based on your specific condition, kidney function, other medications, and medical history. Never adjust your dose without consulting your doctor or pharmacist.
2 DOSAGE AND ADMINISTRATION Administer LIBTAYO as an intravenous infusion over 30 minutes after dilution. ( 2.2 ) Metastatic and locally advanced CSCC and BCC: 350 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months. ( 2.2 ) Adjuvant treatment of CSCC at high risk of recurrence after surgery and radiation: 350 mg every 3 weeks for 12 weeks followed by 700 mg every 6 weeks until disease recurrence, unacceptable toxicity, or up to 48 weeks of total therapy, or 350 mg every 3 weeks until disease recurrence, unacceptable toxicity, or up to 48 weeks of total therapy. ( 2.2 ) NSCLC: 350 mg every 3 weeks until disease progression or unacceptable toxicity. ( 2.2 ) 2.1 Patient Selection for NSCLC Select patients with locally advanced or metastatic NSCLC for treatment with LIBTAYO as a single agent based on PD-L1 expression on tumor cells [see Clinical Studies (14.3) ]. Information on FDA-approved tests for the detection of PD-L1 expression is available at: http